title: The histamine H3 receptor: from discovery to clinical trials with pitolisant.
abstract: The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist (R)alphamethylhistamine which enhances and inhibits, respectively, the activity of histaminergic neurons in brain. The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes. In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies. Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics. Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units. The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.
authors: Centre de recherche, Bioprojet-Biotech, Saint Gregoire Cedex, France. schwartz@bioprojet.com
authors: Jean-Charles
authors: JC
authors: Schwartz
references: Biochem Pharmacol. 2007 Apr 15;73(8):1215-24
references: 17343831
references: Lancet. 2007 Feb 10;369(9560):499-511
references: 17292770
references: Curr Top Med Chem. 2010;10(2):153-69
references: 20166960
references: Eur J Pharmacol. 1990 Apr 25;188(4-5):219-27
references: 1694777
references: Physiol Rev. 1991 Jan;71(1):1-51
references: 1846044
references: Brain Res. 1975 Jul 4;92(1):170-4
references: 1174944
references: Neurosci Lett. 1983 Sep 9;39(3):249-54
references: 6355911
references: Biol Pharm Bull. 2008 Dec;31(12):2163-81
references: 19043195
references: Life Sci. 1975 Aug 15;17(4):503-17
references: 241888
references: Physiol Rev. 2008 Jul;88(3):1183-241
references: 18626069
references: Int Rev Neurobiol. 2007;78:247-87
references: 17349864
references: Annu Rev Pharmacol Toxicol. 1977;17:325-39
references: 194532
references: Nature. 1989 Dec 21-28;342(6252):923-6
references: 2531847
references: Nature. 1975 Jan 31;253(5490):362-4
references: 234179
references: Curr Top Med Chem. 2008;8(11):988-1002
references: 18673168
references: Sleep. 2009 Feb;32(2):175-80
references: 19238804
references: Eur J Pharmacol. 1975 Nov;34(1):157-68
references: 63382
references: Expert Opin Investig Drugs. 2004 Oct;13(10):1237-48
references: 15461554
references: Neurobiol Dis. 2008 Apr;30(1):74-83
references: 18295497
references: Brain Res. 1990 Jul 23;523(2):325-30
references: 2169324
references: J Pharmacol Exp Ther. 2007 Jan;320(1):365-75
references: 17005916
references: Arch Pharm (Weinheim). 2008 Oct;341(10):610-23
references: 18816585
references: Fundam Clin Pharmacol. 1994;8(2):128-37
references: 8020871
references: Nature. 1972 Apr 21;236(5347):385-90
references: 4401751
references: Nature. 2000 Dec 14;408(6814):860-4
references: 11130725
references: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9965-70
references: 11493714
references: Mol Pharmacol. 1999 Jun;55(6):1101-7
references: 10347254
references: Biochem Pharmacol. 2007 Apr 15;73(8):1084-96
references: 17129577
references: J Neurochem. 1970 Nov;17(11):1527-34
references: 5474655
references: Trends Pharmacol Sci. 2004 Dec;25(12):618-25
references: 15530639
references: Sleep Med Rev. 2005 Jun;9(3):185-200
references: 15893249
references: Neurobiol Dis. 2001 Aug;8(4):707-16
references: 11493035
references: Br J Pharmacol. 2000 Dec;131(7):1247-50
references: 11090094
references: Nature. 1975 Jun 19;255(5510):634-5
references: 237236
references: Lancet. 1983 Jan 1;1(8314-5):74-5
references: 6129410
references: J Pharmacol Exp Ther. 1998 Nov;287(2):658-66
references: 9808693
references: Eur J Pharmacol. 1971 Nov-Dec;16(3):326-35
references: 5132560
references: Science. 1974 Nov 29;186(4166):833-5
references: 4157144
references: Eur Neuropsychopharmacol. 2001 Dec;11(6):441-8
references: 11704421
references: Cell. 1999 Aug 20;98(4):437-51
references: 10481909
references: Anal Biochem. 2011 Feb 1;409(1):28-36
references: 20932951
references: Proc Natl Acad Sci U S A. 1984 Apr;81(8):2572-6
references: 6371818
references: Nature. 1983 Apr 28;302(5911):832-7
references: 6188956
references: JAMA. 2009 Mar 18;301(11):1148-54
references: 19293415
references: Nature. 1987 May 14-20;327(6118):117-23
references: 3033516
references: Sleep Med Rev. 2000 Oct;4(5):471-503
references: 17210278